A phase II trial to evaluate a neuroblastoma vaccine in patients with childhood neuroblastoma.

Trial Profile

A phase II trial to evaluate a neuroblastoma vaccine in patients with childhood neuroblastoma.

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Neuroblastoma vaccine (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2015 Planned initiation date changed from 1 Jan 2015 to 1 Jan 2016, as per MabVax media release.
    • 04 Feb 2015 According to MabVax media release, company received an Orphan Drug Designation from FDA in Sept 2014.
    • 06 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top